Press Release

United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market to be Dominated by Supermarkets and Hypermarkets

The increasing concern about pulmonary disease is expected to drive the growth of United Kingdom chronic obstructive pulmonary disease treatment market in the forecast period, 2024-2028.

According to TechSci Research report, “Chronic Obstructive Pulmonary Disease Treatment Market - By Region, Competition, Forecast and Opportunities, 2018-2028”, chronic obstructive pulmonary disease treatment market is anticipated to grow at an impressive rate in the forecast period, 2024-2028. This can be ascribed to the rising demand for effective medicine with medical benefits such as improved lung function, and reduce exacerbations, enhanced exercise capacity and reduced mortality along with growing preference for inhalation device among people facing COPD related issues, across the region. Additionally, rapid advances in science and technology, increasing healthcare expenditure, changes in lifestyle, burgeoning aging population, and rising smoke and pollution through cigarettes and different activities will escalate the growth of United Kingdom chronic obstructive pulmonary disease treatment market in coming years. Besides, the emergence of new products such as triple therapy inhalers, biologic therapies, digital health solutions and anti-inflammatory agents will further be expected to support the United Kingdom chronic obstructive pulmonary disease treatment market growth.

However, the disease burden of chronic obstructive pulmonary disease treatment in United Kingdom can be high, and COPD imposes a significant burden on healthcare systems due to its chronic and progressive nature which can slowing down the growth of United Kingdom chronic obstructive pulmonary disease treatment market in the forecast period. Similarly, despite efforts to raise awareness, COPD remains underdiagnosed and often misdiagnosed. Many individuals with COPD may not seek medical attention until the disease has progressed, leading to delayed diagnosis and intervention which may hamper the United Kingdom chronic obstructive pulmonary disease treatment market growth during the forecast period. Also, some individuals with COPD may face barriers to accessing timely and appropriate care. Factors such as geographical location, socioeconomic status, and healthcare disparities can impact access to healthcare services, including specialist consultations, pulmonary rehabilitation programs, and access to medications which can further restrict the growth of United Kingdom chronic obstructive pulmonary disease treatment market.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on " United Kingdom Chronic Obstructive Pulmonary Disease TreatmentMarket.”

The United Kingdom chronic obstructive pulmonary disease treatment market can be segmented by treatment type, type, distribution channel, and by region.

Based on type, the United Kingdom chronic obstructive pulmonary disease treatment market can be segmented into Chronic Bronchitis, Emphysema. The Chronic Bronchitis Management segment dominated the market in 2022 and is expected to continue maintaining its dominance throughout the forecast period. This can be ascribed to increasing prevalence of smoking and environmental pollution-related bronchial inflammation seen in chronic bronchitis. Furthermore, the emphasis on smoking cessation and prevention measures in recent years may contribute to a larger proportion of COPD patients presenting with chronic bronchitis drinks across the region.

Based on distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital & retail pharmacies segment is expected to dominate during the forecast period. The hospital pharmacies play a significant role in the distribution of COPD medications, particularly for patients admitted in hospitals or those requiring specialized care whereas, retail pharmacies, including community pharmacies or local pharmacies, are easily accessible to the general population. They are a common distribution channel for COPD medications, especially for patients receiving outpatient care or managing their condition in a non-acute setting.

Major companies operating in United Kingdom chronic obstructive pulmonary disease treatment market are:

  • GlaxoSmithKline (GSK) PLC
  • AstraZeneca Ltd
  • Boehringer Ingelheim GmbH
  • Novartis Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Orion Pharma Ltd 
  • Vectura Group Ltd/United Kingdom

In October 2021, GSK has unveiled plans for a new consumer healthcare company's UK headquarters. In addition to its long-term plan for the GSK headquarters, GSK unveiled designs for a significant new UK-based headquarters and worldwide campus for the new Consumer Healthcare company following its separation in 2022

In 2022, Affinivax, Inc., a clinical-stage biopharmaceutical company, will be acquired by GSK for US$2.1 billion, plus up to US$1.2 billion in potential milestone payments. The most cutting-edge vaccinations in this new class are next-generation pneumococcal vaccines, which are being developed by Affinivax

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“United Kingdom chronic obstructive pulmonary disease treatment market is expected to  rise during the forecast period on account of the rising demand for effective medications with medical benefits along with growing preference for personalized treatment plans across the region. Furthermore, trend of personalized medicine is growing, particularly among individuals with COPD-related medical conditions, where generic treatment is specific which will further contribute to the demand for United Kingdom chronic obstructive pulmonary disease treatment market during the forecast period. Besides, increasing concern about healthy lifestyles and increasing expenditure on health and wellness is further expected to create lucrative opportunities for the market growth.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market by Treatment Type (Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiester Type 4 Inhibitor, Mucokinetics, and Others), By Type (Chronic Bronchitis, Emphysema), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2028”, has evaluated the future growth potential of United Kingdom chronic obstructive pulmonary disease treatment market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United Kingdom chronic obstructive pulmonary disease treatment market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com

Relevant News